Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial.

Author: BakkeP S, BjermerL, CrimC, HaumannB, LötvallJ, SanfordL, Scott-WilsonC, SteinshamnS

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Fluticasone furoate/vilanterol (FF/VI) 400/25 μg once-daily demonstrated a good safety profile and improved lung function compared to placebo in patients with chronic obstructive pulmonary disease (COPD).
Paper Details　
Original Abstract of the Article :
Background Fluticasone furoate/vilanterol (FF/VI) is a novel once-daily (OD) inhaled corticosteroid/long-acting β(2) agonist combination in development for chronic obstructive pulmonary disease (COPD) and asthma. Trial design A multicentre, randomised, double-blind, parallel-group, placebo-controll...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263438/

データ提供：米国国立医学図書館（NLM）

A New Inhaler Combination for COPD: Fluticasone Furoate/Vilanterol

Chronic obstructive pulmonary disease (COPD), a debilitating lung condition, affects millions worldwide. This research investigates the efficacy and safety of a novel once-daily inhaled corticosteroid/long-acting β(2) agonist combination, fluticasone furoate/vilanterol (FF/VI), for the treatment of COPD. The study, like a desert expedition exploring uncharted territories, aims to provide new hope for individuals struggling with COPD.

Promising Results: Improved Lung Function and Safety

The results of this study were encouraging, demonstrating that FF/VI significantly improved lung function compared to placebo in patients with COPD. The medication also exhibited a good safety and tolerability profile, with minimal side effects. This is like finding a refreshing oasis in the desert of COPD, offering much-needed relief and a path to improved lung function. It suggests that FF/VI holds promise as a potential new treatment option for COPD patients.

A New Oasis for COPD Patients

The findings of this study offer hope for COPD patients, providing a potential new treatment option that can improve lung function and quality of life. It is like discovering a new oasis in the desert of COPD, offering a haven of relief and a path to better health. This research underscores the importance of continued innovation in the development of new medications for chronic respiratory conditions, striving to alleviate suffering and improve the lives of those affected.

Dr. Camel's Conclusion

This research reminds us that even in the face of challenging diseases, hope and progress are always possible. The development of new and effective treatments for COPD is a testament to the dedication and ingenuity of medical researchers. We must continue to explore new frontiers in medicine, seeking to improve the lives of those who suffer from chronic illnesses.

Date :
  1. Date Completed 2012-10-02
  2. Date Revised 2022-03-09
Further Info :

Pubmed ID

22267687

DOI: Digital Object Identifier

PMC3263438

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.